Jupiter Neurosciences signs $3.33M non-binding term sheet for exclusive U.S. rights to ALA-002 MDMA

JUPITER NEUROSCIENCES, INC.

• Upfront consideration $3.33M ($1.5M cash + $1.83M JUNS stock with 120-day lock-up); $600K escrow deposited.
• Development milestones: $3.33M upon Phase 3 initiation and $20M on FDA approval.
• Commercialization milestones up to $93.33M at net sales thresholds of $333M, $1B, $2B; plus perpetual 3% royalty.
• 90-day exclusivity period; definitive agreement target within 90 days; reverse termination fee of $600K if not executed.
• Deal follows President Trump's April 18, 2026 Executive Order on psychedelic medicine; ALA-002 is an FDA-designated NCE.